PROTEIN DEGRADATION BY THE UBIQUITIN-PROTEASOME PATHWAY IN PATIENTS WITH CHRONIC KIDNEY DISEASE STAGE 5D
https://doi.org/10.24884/1561-6274-2019-23-1-73-78
Abstract
THE AIM: to assess the effect of ubiquitin-independent protein degradation on the development of protein metabolism disorders in patients with CKD who are treated with hemodialysis. PATIENTS AND METHODS: 80 patients with CKD treated with hemodialysis were examined. The study group included: 47 men and 33 women, whose average age was 51.7 ± 11.6 years, the duration of dialysis were 33.5 (0.5; 236) months. An anthropometric study, bioimpedancemetry, determination of muscle strength, biochemical blood analysis and an open ELISA for the presence of a 20S proteasome (20S-PSM) in the blood were carried out to all patients. RESULTS: When building regression analysis models, age, duration of dialysis, serum albumin, 20S proteasomes had a significant effect on muscle strength. There was no statistically significant correlation between the level of 20S-PSM and serum albumin and total protein as an independent result of proteasome protein degradation (p = 0.78; p = 0.80). CONCLUSION: The study demonstrated the relationship of the level of 20S proteasome with the features of dialysis treatment, the level of chronic inflammation. The change in body composition in the form of a compensatory increase in the absolute content of adipose tissue on the background of sarcopenia was not revealed according to the results of bio-impedance, which requires further study.
About the Authors
N. B. Bondarenko
Department of Internal Medicine №2, Rostov State Medical University
Russian Federation
Russian Federation
Nikolay B. Bondarenko, MD
344022, Rostov-on-Don, Nakhichevansky Ln, 29.
Rostov State Medical University, Internal Medicine Department #2, postgraduate student.
Phone: +79508511562
M. M. Batushin
Department of Internal Medicine №2, Rostov State Medical University
Russian Federation
Russian Federation
Prof. Michail M. Batyushin MD, PhD, DMedSci
344022, Rostov-on-Don, Nakhichevansky Ln, 29. Rostov State Medical University, Internal Medicine Department #2.
Phone: +79185018801
M. Z. Gasanov
Department of Internal Medicine №1, Rostov State Medical University
Russian Federation
Russian Federation
Associate professor Mithat Z. Gasanov MD, PhD
344022, Rostov-on-Don, Nakhichevansky Ln, 29. Rostov State Medical University, Internal Medicine Department #1, associate professor.
Phone: +79889473750
I. V. Sarvilina
Medical center «Novomedicine», Rostov-on-Don
Russian Federation
Russian Federation
Irina V. Sarvilina
344022, Rostov-on-Don, str. Socialisticheskaya, 74, Business center “Kupechesky Dvor” office 1030, Medical center «Novomedicine», Chief Physician.
Phone: +7903-436-48-66
O. V. Golubeva
«Hemodialysis Centre Rostov», Rostov-on-Don
Russian Federation
Russian Federation
Oksana V. Golubeva, MD
344029, Rostov-on-Don, str. Of 1st Konnoy Army, 33, LLC «Hemodialysis Centre Rostov», Chief Physician.
Phone: +7903-436-48-66
References
1. Бикбов БТ, Томилина НА. Заместительная терапия терминальной хронической почечной недостаточности в Российской Федерации в 1998–2013 гг. Отчет по данным Российского регистра заместительной почечной терапии. Часть первая. Нефрология и диализ 2015. Приложение к Т. 17; 3: 5–111 [Bikbov BT, Tomilina NA. Renal replacement therapy for ESRD in Russian Rederation, 1998-2013. Report of the Russian Renal Replacement Therapy Registry. Part 1. Nephrology and dialysis 2015. App. to T. 17; 3: 5–111]
2. Androga L, Sharma D, Amodu A et al. Sarcopenia, Obesity, and Mortality in US Adults With and Without Chronic Kidney Disease. Kidney Int Rep 2017 Mar; 2(2): 201–211. Doi: 10.1016/j. ekir.2016.10.008
3. Ren H, Gong D, Jia F et al. Sarcopenia in patients undergoing maintenance hemodialysis: incidence rate, risk factors and its effect on survival risk. Renal Failure 2016; 38 (3): 364–371. Doi: 10.3109/0886022X.2015.1132173
4. Sayer AA, Robinson SM, Patel HP et al. New horizons in the pathogenesis, diagnosis and management of sarcopenia. 2013 Mar; 42(2): 145–150. Doi: 10.1093/ageing/afs191
5. Kaizu Y, Ohkawa S, Odamaki M et al. Association between inflammatory mediators and muscle mass in long-term hemodialysis patients. Am J Kidney Dis 2003; 42 (2): 295–302
6. Бунеева ОА, Медведев АЕ. Убиквитин-независимая деградация белков в протеасомах. Биомедицинская химия 2018; 64(2): 134–148 [Buneeva OA, Medvedev AE. Ubikvitin-nezavisimaya degradaciya belkov v proteasomah. Biomedicinskaya himiya 2018; 64(2): 134–148]
7. Raynes R, Pomatto LC, Davies KJ. Degradation of oxidized proteins by the proteasome: Distinguishing between the 20S, 26S, and immunoproteasome proteolytic pathways. Mol Aspects Med 2016 Aug;50: 41–55. Doi: 10.1016/j.mam.2016.05.001
8. Rom O, Reznik AZ. The role of E3 ubiquitin-ligases MuRF-1 and MAFbx in loss of skeletal muscle mass. Free Radic Biol Med 2016 Sep; 98: 218–230. Doi: 10.1016/j.freeradbiomed.2015.12.031
9. Deger SM, Hung AM, Gamboa JL et al. Systemic inflammation is associated with exaggerated skeletal muscle protein catabolism in maintenance hemodialysis patients. JCI Insight 2017 Nov 16; 2(22); pii: 95185. Doi: 10.1172/jci.insight.95185
10. Correa-de-Araujo R, Harris-Love MO, Milkovic I et al. The need for standardized assessment of muscle quality in Skeletal Muscle Function Deficit and other aging-related muscle dysfunction: a symposium report. Front Physiol 2017; 8: 87. Doi: 10.3389/fphys.2017.000.87
Review
For citations:
Bondarenko N.B., Batushin M.M., Gasanov M.Z., Sarvilina I.V., Golubeva O.V. PROTEIN DEGRADATION BY THE UBIQUITIN-PROTEASOME PATHWAY IN PATIENTS WITH CHRONIC KIDNEY DISEASE STAGE 5D. Nephrology (Saint-Petersburg). 2019;23(1):73-78. (In Russ.) https://doi.org/10.24884/1561-6274-2019-23-1-73-78
Views:
910
Email this article 